Zdrowie i gospodarka · 10/02/2006
FDA Clears PEPTAVLON for Subcutaneous Injection
The FDA has determined that PEPTAVLON (pentagastrin) for subcutaneous injection, 0.25 mg/mL, was not withdrawn from sale due to safety or effectiveness concerns, paving the way for approval of abbreviated new drug applications (ANDAs) for this treatment.
Source: Federal Register — Food and Drug AdministrationOpen original release →